leadf
logo-loader
viewSienna Cancer Diagnostics Ltd

Sienna Cancer Diagnostics achieves first sale of cancer test in Switzerland

The company’s in-vitro diagnostic test help urologists detect bladder cancer earlier.

cancer cells
Sienna listed on the ASX in 2017 after raising $4.6 million

Sienna Cancer Diagnostics Ltd (ASX:SDX) has achieved the first sale of its hTERT cancer test in Switzerland through its distribution partner, Biosystems Switzerland AG.

The company’s in-vitro diagnostic (IVD) hTERT test help urologists to detect bladder cancer earlier.

Sienna’s primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009.

Telomerase is well recognised as a remarkable biomarker used by 85% of cancers to enable immortal cell replication.

Clinical validation completed by the customer

Following the signing of Biosystems Switzerland as the exclusive distributor for Switzerland of Sienna’s novel IVD test, the first order by a Swiss laboratory has been delivered.

This follows training of Biosystems key personnel by Sienna in late 2017, and evaluation and clinical validation by the customer.

A biomarker test for diagnosing bladder cancer

Although urine cytology is non-invasive, it has significant limitations in terms of sensitivity, particularly when it comes to low-grade or early-stage bladder cancer.

Having a biomarker test that can provide additional clinically significant information for the diagnosing physician, while using the same urine sample collected for cytology, adds real value to the diagnostic process.

Biosystems Switzerland has generated a pipeline of interested laboratories, several of which are well advanced in evaluating the test for clinical use.

READ: Sienna Cancer Diagnostics to launch its in-vitro test in Denmark and Sweden

Sienna listed on the ASX in 2017 following a successful initial public offer (IPO) which raised $4.6 million.

The company achieved significant milestones in 2017, including FDA registration of its IVD product in the U.S. and CE Mark approval and IVD registration in the Europe Union.

Sienna’s near-term objective is to maximise growth opportunities in the U.S., with significant interest already shown by pathology laboratories in the hTERT test.

Quick facts: Sienna Cancer Diagnostics Ltd

Price: - -

ASX:SDX
Market: ASX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan first half: 'period of integration, restructuring and setting...

Proactive Analyst Emma Ulker talks through how Open Orphan (LON:ORPH) performed in the first half of the year.  In the six-month period to June 2020, the company focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in...

4 hours, 48 minutes ago

2 min read